Uses of Maykary

Maykary is an antibiotic that is prepared in the form of an intravenous solution with the main ingredient Ciprofloxacin. To ensure safety for health and maximize the effectiveness of treatment, patients need to take Maykary exactly as directed by their doctor.

Each bag (100mL) of Maykary intravenous solution contains: Ciprofloxacin hydrochloride equivalent to Ciprofloxacin 200mg. Ciprofloxacin is a quinolone antibiotic. Ciprofloxacin has a good effect on bacteria resistant to antibiotics of other groups (Aminoglycosides, Cephalosporins, Tetracyclines, Penicillins...) and is considered one of the most potent drugs in the Fluoroquinolone group.

Maykary contains Ciprofloxacin which is an antibiotic of the Quinolone group, suitable for the treatment of infections caused by susceptible strains of bacteria in the following cases:
Upper and lower respiratory tract infections: Caused by Escherichia coli, Klepsialla pneumoniae, Enterobacter coacae, Proteus mirabilis, Pseudomonas aeruginosa. Skin and soft tissue infections: Caused by E. coli, K. pneumoniae, Providencia stuartii, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis (cases resistant to methicillin). Bone and joint infections: Specifically caused by Enterobacter cloacae, Serratia marcescens or Pseudomonas aeruginosa as well as general intestinal bacteria Urinary tract infections: Upper urinary tract infections: Caused by Escherichia coli, Klepsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citribacterfreundii, Pseudomonas aeruginosa. Lower urinary tract infections: For example, chronic prostatitis, chronic cystitis caused by gram-negative bacteria resistant to penicillins and cephalosporins. Infections of the genital organs: Maykary is used in the treatment of soft tissue ulcers, gonorrhea caused by multidrug-resistant strains of gonorrhea. Gastrointestinal infections: Combination of other antibiotics with anaerobic activity to eradicate multidrug-resistant gram-negative bacteria. Sepsis, endocarditis: Caused by resistant strains of gram-negative bacteria, Q fever endocarditis (Coxiella burnetii). Prostatitis. Prophylaxis of meningococcal disease and bacterial infections in immunocompromised people.

General instructions on dosage of Maykary: The dose of Ciprofloxacin intravenously is determined based on the type of infection, severity, and susceptibility of the pathogenic bacteria; age, weight, and renal function of the patient.
Adults: The recommended dose is 100-200mg every 12 hours. However, in patients with sepsis, systemic infections caused by Pseudomonas aeruginosa and in patients with leukopenia, the recommended dose is 200-400 mg every 8 hours.
The duration of treatment depends on the severity of the infection, the clinical response and the causative organism. The duration of treatment for acute infections is usually 5 to 7 days. In general, ciprofloxacin should be taken continuously for at least 3 days after the signs and symptoms of infection have resolved.
How to use: Maykary is administered intravenously for a minimum of 60 minutes.
Elderly: Despite high plasma concentrations of Ciprofloxacin in the elderly, no dose adjustment is required.
Children under 16 years: Like other Quinolone antibiotics, Ciprofloxacin can cause joint disease.

Maykary is contraindicated in the following subjects:
People who are sensitive to Ciprofloxacin, Quinolone antibiotics or any of its ingredients. The patient has a history of tendon disorders, tendinitis, or tendon rupture. Children under 16 years old: Except for cystic fibrosis and prevention of Anthrax that causes lung disease. Pregnant women and lactating women.

As with other Fluroquinolones, cases of tendinitis, which commonly affects the Achill tendon, have been reported, which can lead to tendon rupture. In the case of tendinitis, the drug should be discontinued and the patient should be fully immobilized, a physician should be consulted. Predisposing factors for the occurrence of tendinitis are people over 60 years of age, excessive exercise, and prolonged use of corticosteroids. Patients should be warned about Achill tendon pain (ankle and heel pain). Cystic fibrosis in children: Analysis of safety data on drug use in children and adolescents under 18 years of age, the majority of patients with cystic fibrosis, did not see cartilage and joint damage due to drug use. Clinical and pharmacokinetic data confirm the use of ciprofloxacin in patients with cystic fibrosis as well as in the treatment of acute lung disease caused by Pseudomonas aeruginosa. Therefore, the use of Maykary is contraindicated in children except in cases of cystic fibrosis. In rare cases, Eiprofloxacin may cause photosensitizing reactions in some patients with cystic fibrosis. Therefore, patients should avoid prolonged sun exposure during treatment with Ciprofloxacin. Maykary may stimulate the central nervous system leading to anxiety, headache, light restlessness, confusion, and very rarely hallucinations or convulsions. Therefore, it should be used with caution in patients with known or suspected CNS disorders such as cerebral arteriosclerosis, epilepsy, or in the presence of diagnostic factors for these conditions. Caution in patients with impaired liver/renal function, G6PD deficiency, myasthenia gravis. Pseudomembranous colitis is common with most antibiotics. Pregnant women: After intravenous doses up to 20mg/kg body weight, no maternal, fetal toxicity and teratogenicity were observed. Ciprofloxacin causes arthropathy in young animals, so its use during pregnancy is not recommended. Lactation: Ciprofloxacin is excreted in human milk. Because of the potential adverse effects seen in nursing infants when mothers receive ciprofloxacin, a decision should be made whether to discontinue nursing or discontinue the drug. Driving and using machines: Ciprofloxacin may cause a decrease in the response time to the emotional range, affecting the ability to drive and use machines. This is especially true when taken with alcohol.

On the digestive tract: Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, anorexia, flatulence. If you have severe diarrhea during or after taking the medicine, see your doctor because it could be a serious disorder in your intestines (pseudoconjunctivitis). In this case, discontinue ciprofloxacin and initiate appropriate therapy (eg, vancomycin 250 mg administered 4 times in 24 h). The drug is contraindicated in cases of resistance to intestinal motility. Central nervous system: Dizziness, headache, fatigue, anxiety, terror. Very rare: Sweating, loss of balance, sleeping eyes, somnolence, hallucinations, mood swings, unsteadiness, ataxia, convulsions, somnolence, anorexia, paresthesia, anxiety, depression , stress, confusion, peripheral paralysis. In some cases, these side effects may appear soon after taking the first dose. Skin/ Hypersensitivity: In some cases, these effects sometimes appeared immediately after the first dose. Skin reactions such as: rash, itching, fever due to the drug.

Like other Quinolone antibiotics, concomitant administration of Ciprofloxacin with Theophyllin leads to increased concentrations and prolongation of the half-life as well as increased side effects of Theophyllin. If concomitant use cannot be avoided, theophyllin concentration should be monitored and the dose adjusted. Certain quinolones, including ciprofloxacin, inhibit the metabolism of caffeine and may lead to a decrease in caffeine clearance. Combination of high-dose quinolones with non-steroidal anti-inflammatory drugs (except Acetyl salicylic) increased seizures in clinical studies. Ciprofloxacin increases the effect of oral anticoagulants (such as Warfarin). When these preparations are administered concurrently, prothrombin time or other appropriate coagulation tests should be monitored. Ciprofloxacin increases serum creatinine concentration when used concomitantly with Cyclosporine. Concomitant administration of Ciprofloxacin with Glybenclamide in some patients caused severe hypoglycaemia. Probenecid interferes with tubular secretion and increases serum concentrations of ciprofloxacin. Phenyltoin concentrations are altered (increased or decreased) by concomitant administration of ciprofloxacin. Metoclopromide increases the absorption of ciprofloxacin, resulting in rapid peak serum concentrations of ciprofloxacin, but without affecting bioavailability. Inhibition of methotrexate renal tubular transport when co-administered with ciprofloxacin may result in increased concentrations and increased toxic effects of methotrexate. Above is important information about the uses, dosage and precautions when using Maykary. Note, this is a prescription drug, patients do not arbitrarily use to ensure safety for health.